Inflammation IL-6 dan hsCRP and Prostate Hyperplasia on Ab-Ob
69 0,71 0,15-3,62 pgdL and 1,45 0,3-13,5 vs 1,00 0,2-9,2 mgL.
This result may be cause by mean in case group or control group than have normal IL-6 level. Interleukin and acute phase reactant
levels very fluctuate in plasma so that can’t describe reality condition. In other hand condition that may be affect sample in this
research was taken operative patient so that cytokines load will be decrease parallel with decrease of prostate mass after hyperplasia.
Cross sectional study by Saadi
et al.,
find that if hsCRP and IL-6 the highest level was in BPH group with LUTS if compare
with BPH group alone or with normal people This study involve 56 sample that divided by 3 group, BPH+LUTS group, BPH alone
and healthy people. hsCRP level mean for each group was 10,04±1,58; 5±0,36; 2,8±0,5 mgL with p0,001. IL-6 level mean
was 14,56±1,1; 8,82±0,93; 12,6±0,82 with p0,001 Saadi
et al.,
2012. Other study by Hung et al., find there is significant correlation
between hsCRP to prostate volume Hung
et al.,
2014. This study was a cross sectional with high sample size that involve 853
sample. Mean of hsCRP level on subject base characteristic was 3,1±0,43 mgdL, significantly correlated to IPSS score with
correlation coefficient r=0,151, p0,001.
If we compare our research, we find that a very low level of IL-6 on Ab-OB group with prostate hyperplasia, even with range
between 0,25-3,72 mgdL. There is a high influence to insignificant results of IL-6 and hsCRP that increase risk of BPH
on Ab-OB although conceptually and theoretically inflammation have a central role in correlation between fibrosis and prostate
hyperplasia.
In this research we only find that there is a tendency of IL-6 and hsCRP higher than case group if compare with control group.
IL-6 and hsCRP level in our research lower than other study above. Several epidemiologic study show that 25 of malignancy
correlated with chronic inflammation and 15 death case from cancer caused by inflammation Hsing, 2007; Burton
et al.,
2007. Release of inflammation mediator that chronically happen and
excessive theorically considered cause increase initiation,
70 promotion and progression of tumor Lehrer
et al.,
2005; Bruton
et al.,
2007.
On obesity, adipose tissue in chronic inflammation condition, which have important role to insulin resistance, dyslipidemia
accuracy and also other comorbidity disease such as cardiovascular disease and cancer. This inflammation is being mark with elevation
CRP level, IL-6, IL-8, MCP- 1 and TNFα.
Mechanism that explained how obesity induced chronic inflammation can increase prostate hyperplasia include: ii
elevation proinflammation mediator production such as cytokine, chemokine, ROI, ii increase oncogene expression, COX-2, 5-
LOX, and MMPs, iii elevation pro inflammation transcription factor, such as NF-
κB, STAT3, AP-1.
Infiltration from chronic inflammation often happen at peripheral side of the prostate. Inflammation described with PMN
infiltration, cytokine and chemokine including CRP. CRP also release from adipose tissue. CRP is acute phase protein that
secreted from liver and unspecific marker for inflammation, infection, tissue damage. This inflammation mediator will
inducedother proinflammation transcription factor such as NF-
κB and iNOS. NF-
κB was strong inducer from gene that related to anti apoptosis activity and gene that arrange cell cycle life cyclin
D1. NF- κB and iNOS are very important role in cellular immune
activity, had antimitogenic and antiapoptosis effect. Activation NF-
κB and iNOS by proinflammtion cytokine will induce tumour
cell initiation and progressivity.
Proinflammation cytokine will also induce PMN to produce ROS and RNS, which next induce DNA mutation and form tumor.
Infection and releasing proinflammation cytokine caused by chronic inflammation on prostate will cause lesion like PIA,
whereas the focal atrophy on prostate tissue with epithel tissue proliferation and inflammation cells infiltration.
In this research there is no prove that Ab-Ob with high level of CRP and IL-6 level have more risk to prostate hyperplasia if
compared with Ab-Ob without prostate hyperplasia.
71